NCIC CLINICAL TRIALS GROUP

INVESTIGATIONAL NEW DRUG COMMITTEE

OPEN MEETING AGENDA
Delta Chelsea, Toronto. Room: Churchill A

Friday April 29, 2011 ~ 13.30pm – 16.30pm
Room: Churchill (A)
Chair: Dr. Kim Chi
IND Program Directors: Drs. Elizabeth Eisenhauer and Lesley Seymour

1:30 pm: Welcome Dr. Kim Chi

Mature trial reports and discussion:

1:30 pm: IND.177: Phase I trial cdk inhibitor AT 7519M (10’)
Dr. Sebastien Hotte
Update on cdk inhibitors in clinical trials (15’)
Dr. Janet Dancey

1:55 pm IND.187: Phase I trial of PARP inhibitor AZD2281 + irinotecan (10’)
Dr. Eric Chen
Update on PARP inhibitors in clinical trials (15’)
Dr. Rebecca Dent

2:00 pm IND. 195: Interim results of clinical and circulating tumour cell study
of SB939 in prostate cancer (15’)
Dr. Kim Chi

2:35 pm COFFEE/TEA

2:55 pm IND.192: Ridaforolimus in endometrial cancer (10’)
Dr. Helen Mackay
and Update on mTOR inhibitors (10’)

3:15 pm Genomic based treatment selection: clinical trial of the future
Dr. Lillian Siu

3:35 pm Teaching old drugs new tricks: drug discovery in hematological malignancies
Dr. Aaron Schimmer

4:00 pm Update on ongoing and planned IND trials
Dr. E. Eisenhauer
Pediatric IND Report
Dr. Sylvain Baruchel

4:30 pm ADJOURN

IND OPEN COMMITTEE MEETING OBJECTIVES

- To summarize aspects of recent developments in the understanding of molecular biology and therapeutics as these relate to specific malignancies and their therapeutic targets
- To describe and discuss results of recent Investigational New Drug studies conducted by the NCIC Clinical Trials Group
- To understand aspects new clinical trial methodologies in the field of early cancer drug development